Continuous ambulatory peritoneal dialysis (CAPD) is a form of renal replacement therapy for patients with end-stage kidney disease. Older patients with multiple comorbidities who desire home therapy is an indication for CAPD. Diabetes mellitus and old age produce senescence of the immune system and predispose patients to catheter-related infections. Peritoneal dialysis and in particular CAPD are associated with a high risk of peritonitis, tunnel infection (TI) and catheter exit-site infection (ESI). [1] Catheter ESI and TI are a major source of morbidity. ESI and TIs increase the risk of catheter loss, peritonitis and overall PD technique failure. [2] Majority of the ESIs are caused by Gram-positive organisms and can be successfully treated by appropriate antimicrobial therapy for a period of 2-3 weeks without catheter loss. [3] Non-tuberculous mycobacterium (NTM) is a very rare cause of ES and TI and requires catheter removal for management along with antimicrobial therapy. Mycobacterium abscessus is a rapidly growing NTM and rarely causes TI among PD patients. It is usually difficult to treat M. abscessus because of its resistant nature to most of the antibiotics. [4] TI may present as erythema, oedema or tenderness over the subcutaneous site but is often clinically occult, as shown by ultrasound studies. [5] TI usually occurs in the presence of an ESI but rarely occurs alone. Here, we described an early onset of NTM in an 82-year-old T2D patient on CAPD.
In September 2018, he presented with complaints of discharge and redness around the peritoneal dialysis catheter exit site (ES). Swab from the ES grew Staphylococcus hominis for which he was started on quinolones as per sensitivity. Ultrasonographic screening of the catheter tunnel showed no evidence of infection. After 2 weeks on antibiotics, he came with persistent mucopurulent discharge from the ES. He had no history of fever and abdominal pain, and PD effluent was clear. There were redness and mild sprouting of flesh around the ES. There were no warmth and tenderness around the ES. Investigations showed WBC of 6100 cells/mm 3 (polymorph -79.1%, lymphocyte -14.7%, monocyte -4.4% and eosinophil -1.6%), Hb -10.5 g/dl, platelet -187,000/cu.mm, total protein -5.1 g/dl and serum albumin -2.7 g/dl. Ultrasonography showed subcutaneous tunnel collection, and the ES was explored under general anaesthesia which confirmed TI extending from ES to anterior rectus sheath with sparing of the inner cuff [ Figure 1 ].
The tract with unhealthy granulation tissue was excised in total. The extraperitoneal portion of the PD catheter was rerouted medially, and new ES was created away from the previous exit. He was continued on CAPD without interruption. The excised exit tissue showed acid-fast bacilli (on Ziehl-Neelsen stain and Auramine O stain). Histopathological examination showed features suggestive of acute on chronic inflammation. Following this, he was started on four drug antituberculous regimens (HRZE). Bacterial cultures did not yield any growth. Automated liquid TB culture was put on the MGIT 360 (Beckton Dickenson). The MGIT 360 flagged positive after 2 weeks of incubation. Following sterility check, the organism was tested by the MPT64 antigen detection by immunochromatography for the presence of Mycobacterium tuberculosis and found to be negative. The isolate was then grown on Lowenstein-Jensen media and identified by Vitek MS (nioMeriuex, France) as Mycobacterium abscesses. The antituberculous drugs were switched over to oral clarithromycin 500 mg twice daily, oral ofloxacin 400 mg once daily and amikacin 500 mg intravenous injection once in 2 days. He is on the above regimen for 7 weeks, and the skin shows two discharging sinuses [ Figure 2 ] without peritonitis. The patient has been advised catheter removal and reimplantation of a new catheter concurrently through a new entry point. The patient has not made a decision for the procedure, and he is being followed up with ultrasound of tunnel every 2 weeks to see the progress of therapy.
disCussiOn
Peritonitis remains a leading complication of PD which accounts for 18% of the infection-related mortality in PD patients. An ESI is defined by the presence of purulent drainage, with or without erythema of the skin at the catheter-skin interface. Pericatheter erythema without purulent discharge is sometimes an early indication of infection but can also be a simple skin reaction, particularly in a recently placed catheter or after trauma to the catheter. [5] ESI and TI are associated with an increased risk of peritonitis. The incidence of ESI in PD patients ranges from 0.05 to 1.02 episodes per patient-year. The incidence of ESIs is seen anywhere between one episode in 27.3 patients' months to one episode in 41.9 patients' months. [6] The diagnosis of TI is mainly based on clinical suspicion and ultrasound examination. The extent of involvement of the subcutaneous PD catheter tract is a critical factor in the development of peritonitis. [6] The most common organism associated with ESI and TI is Staphylococcus aureus and Pseudomonas aeruginosa. The incidence of mycobacterial infections has grown rapidly over the last few years. In particular, non-tuberculous mycobacterial infections, especially those caused by Mycobacterium fortuitum and Mycobacterium chelonae, are becoming highly prevalent. However, peritoneal catheter ESIs are very rare. [7] M. abscessus is a rapidly growing NTM that requires 1-3 weeks to grow and was named after its ability to produce deep subcutaneous abscess. [8] These mycobacteria have an affinity for the dermis and the subcutaneous area, and in a non-immunosuppressed patient, protective factors within the peritoneum contain the infection, which is not the case with CKD. [9] Infections due to M. abscessus are usually refractory to medical treatment because this organism is intrinsically resistant to many of the currently available antituberculous drugs and antibiotics. The drugs currently recommended for the treatment of M. abscessus infections are a combination therapy of clarithromycin with one aminoglycoside and one other injectable drug such as cefoxitin or imipenem. Macrolides are the only active oral antibiotic against M. abscessus. [10] Treatment modalities also include removal of the infected catheter and simultaneous replacement with a new catheter. Close interaction between the clinical microbiologist and nephrologists is the key to successful diagnosis and treatment of patients.
We identified ten cases of ESIs and/or TIs due to M. abscessus in the literature of which, only four cases had TIs. [4, [11] [12] [13] All the patients with M. abscessus infection ended up in catheter Table 1 ]. Our patient presented with persistent discharge, and his PD catheter was rerouted and started on empirical antibiotic therapy. M. abscessus was identified on tissue culture. He responded well to the treatment and continued on peritoneal dialysis. If there has been a delay in diagnosis, the infection would have progressed to peritonitis, And catheter removal would have been the only option.
Our patient had two swab cultures that grew bacteria but did not respond to antibiotics. That prompted us to do a tissue culture that isolated the M. abscessus which highlighted the fact that NTM and M. tuberculosis cannot be isolated from swabs. Hence, there should be a high realm of suspicion of NTM in a patient with persistent ESI/TI, despite appropriate antibiotic therapy in case of non-responsiveness. The only method to obtain microbiological evidence is through tissue culture from the wall of the cavity, which is very difficult to obtain and takes 3 weeks to isolate from culture leading to delayed treatment, which makes clinical diagnosis the best option. Appropriate culture media should be used or routine culture should be prolonged following discussion with the microbiologist. Early diagnosis and prompt treatment with combination antibiotics may help to prevent the catheter loss.
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